AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G] Celldex Therapeutics, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,000,000 Shares (as defined in Item 2(a)) issuable upon exercise of call options.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,000,000 Shares issuable upon exercise of call options.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,000,000 Shares issuable upon exercise of call options.


SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:07/10/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:07/10/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:07/10/2025
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

Celldex Therapeutics Inc

NASDAQ:CLDX

CLDX Rankings

CLDX Latest News

CLDX Latest SEC Filings

CLDX Stock Data

1.69B
66.22M
0.19%
111.59%
11.72%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
United States
HAMPTON